🎉 M&A multiples are live!
Check it out!

Rigel Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Rigel Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Rigel Pharmaceuticals Overview

About Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.


Founded

1996

HQ

United States of America
Employees

164

Website

rigel.com

Financials

LTM Revenue $185M

LTM EBITDA $26.0M

EV

$290M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Rigel Pharmaceuticals Financials

Rigel Pharmaceuticals has a last 12-month revenue of $185M and a last 12-month EBITDA of $26.0M.

In the most recent fiscal year, Rigel Pharmaceuticals achieved revenue of $179M and an EBITDA of $28.5M.

Rigel Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Rigel Pharmaceuticals valuation multiples based on analyst estimates

Rigel Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $117M $179M XXX XXX XXX
Gross Profit $118M $110M XXX XXX XXX
Gross Margin 101% 61% XXX XXX XXX
EBITDA -$17.0M $28.5M XXX XXX XXX
EBITDA Margin -15% 16% XXX XXX XXX
Net Profit -$58.6M -$25.1M XXX XXX XXX
Net Margin -50% -14% XXX XXX XXX
Net Debt $15.0M $26.8M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Rigel Pharmaceuticals Stock Performance

As of April 15, 2025, Rigel Pharmaceuticals's stock price is $17.

Rigel Pharmaceuticals has current market cap of $307M, and EV of $290M.

See Rigel Pharmaceuticals trading valuation data

Rigel Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$290M $307M XXX XXX XXX XXX $1.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Rigel Pharmaceuticals Valuation Multiples

As of April 15, 2025, Rigel Pharmaceuticals has market cap of $307M and EV of $290M.

Rigel Pharmaceuticals's trades at 1.6x LTM EV/Revenue multiple, and 11.2x LTM EBITDA.

Analysts estimate Rigel Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Rigel Pharmaceuticals and 10K+ public comps

Rigel Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $290M XXX XXX XXX
EV/Revenue 1.6x XXX XXX XXX
EV/EBITDA 10.2x XXX XXX XXX
P/E 17.6x XXX XXX XXX
P/E/Growth 0.4x XXX XXX XXX
EV/FCF 9.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Rigel Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Rigel Pharmaceuticals Valuation Multiples

Rigel Pharmaceuticals's NTM/LTM revenue growth is 12%

Rigel Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Rigel Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Rigel Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Rigel Pharmaceuticals and other 10K+ public comps

Rigel Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 53% XXX XXX XXX XXX
EBITDA Margin 16% XXX XXX XXX XXX
EBITDA Growth -268% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 28% XXX XXX XXX XXX
Revenue per Employee $1.1M XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 13% XXX XXX XXX XXX
Opex to Revenue 76% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Rigel Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Rigel Pharmaceuticals M&A and Investment Activity

Rigel Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Rigel Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Rigel Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Rigel Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Rigel Pharmaceuticals

When was Rigel Pharmaceuticals founded? Rigel Pharmaceuticals was founded in 1996.
Where is Rigel Pharmaceuticals headquartered? Rigel Pharmaceuticals is headquartered in United States of America.
How many employees does Rigel Pharmaceuticals have? As of today, Rigel Pharmaceuticals has 164 employees.
Who is the CEO of Rigel Pharmaceuticals? Rigel Pharmaceuticals's CEO is Mr. Raul R. Rodriguez.
Is Rigel Pharmaceuticals publicy listed? Yes, Rigel Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Rigel Pharmaceuticals? Rigel Pharmaceuticals trades under RIGL ticker.
When did Rigel Pharmaceuticals go public? Rigel Pharmaceuticals went public in 2000.
Who are competitors of Rigel Pharmaceuticals? Similar companies to Rigel Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Rigel Pharmaceuticals? Rigel Pharmaceuticals's current market cap is $307M
What is the current revenue of Rigel Pharmaceuticals? Rigel Pharmaceuticals's last 12-month revenue is $185M.
What is the current EBITDA of Rigel Pharmaceuticals? Rigel Pharmaceuticals's last 12-month EBITDA is $26.0M.
What is the current EV/Revenue multiple of Rigel Pharmaceuticals? Current revenue multiple of Rigel Pharmaceuticals is 1.6x.
What is the current EV/EBITDA multiple of Rigel Pharmaceuticals? Current EBITDA multiple of Rigel Pharmaceuticals is 11.2x.
What is the current revenue growth of Rigel Pharmaceuticals? Rigel Pharmaceuticals revenue growth between 2023 and 2024 was 53%.
Is Rigel Pharmaceuticals profitable? Yes, Rigel Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.